Agenus (AGEN)
(Delayed Data from NSDQ)
$5.36 USD
-0.16 (-2.90%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $5.34 -0.02 (-0.37%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth D Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AGEN 5.36 -0.16(-2.90%)
Will AGEN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AGEN
Zacks.com featured highlights include QuantumScape, Civeo and Agenus
QuantumScape & 2 Other Stocks to Buy for Earnings Acceleration
AGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is CVS Health (CVS) Stock Outpacing Its Medical Peers This Year?
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
Other News for AGEN
Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report | AGEN Stock News
Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral ...
Agenus unit, MiNK surges after peer-reviewed data for lead drug
12 Health Care Stocks Moving In Monday's Intraday Session
Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward ...